PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
16.61%
Some net income increase while GNPX is negative at -24.13%. John Neff would see a short-term edge over the struggling competitor.
4.17%
D&A growth well above GNPX's 5.19%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-100.00%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-2.08%
Both cut yoy SBC, with GNPX at -0.30%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-115.45%
Both reduce yoy usage, with GNPX at -47.23%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.13%
Negative yoy AP while GNPX is 210.60%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-68.80%
Both reduce yoy usage, with GNPX at -99.34%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
119.47%
Well above GNPX's 107.77%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
9.84%
Some CFO growth while GNPX is negative at -40.42%. John Neff would note a short-term liquidity lead over the competitor.
98.37%
CapEx growth well above GNPX's 95.06%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.37%
Investing outflow well above GNPX's 95.30%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
64.41%
Debt repayment growth of 64.41% while GNPX is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-34.38%
Negative yoy issuance while GNPX is 102.68%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.